Benzodiazepine self-administration in humans and laboratory animals - implications for problems of long-term use and abuse
The DOI matches its Crossref record; 205 of the 205 references it cites were found in a registry or an index.
Abstract
Drug reinforcement may represent the primary behavioral-pharmacological mechanism underlying two types of problematic use of benzodiazepines--recreational abuse by polydrug abusers and inappropriate chronic use by patients. High dose polydrug abuse for the purpose of getting high is readily recognized as a significant social problem. Inappropriate chronic benzodiazepine use is more subtle but relatively common: for anxiolytics, 36% of past-year users (3% of the adult population in the US) report using these drugs for 4 consecutive months or longer. The risks of such long-term use are much better documented than the benefits. This paper provides a current review of various problems that have been identified with the long-term use and the recreational abuse of benzodiazepines, including memory impairment, risk of accidents, falls and hip fractures in the elderly, a withdrawal syndrome, brain damage, overuse in the elderly, overuse by chronic pain patients, overuse by alcoholics and recreational abuse among alcoholics and polydrug abusers. A comprehensive review of the literature on benzodiazepine reinforcing effects in humans and laboratory animals is also provided. Drug self-administration studies in humans and laboratory animals provide models of both types of problematic benzodiazepine use. Recreational abuse of benzodiazepines has been modeled in human research with polydrug abusers and in laboratory animal studies, which show that the reinforcing effect of benzodiazepines is intermediate relative to other sedative compounds and is increased in subjects with histories of previous sedative drug self-administration. The problem of inappropriate long-term use of benzodiazepines by people without histories of drug abuse has been partially modeled in human studies showing that benzodiazepines function as reinforcers in subjects with anxiety, insomnia, and histories of moderate alcohol consumption, and in preclinical studies showing stable, low-rate benzodiazepine self-injection with concurrent physical dependence under conditions of continuous availability. Both human and animal research suggests that the drug history and current behavioral context may be important in the establishment of benzodiazepines as reinforcers. Limited human and animal research provides little support for the common belief that physical dependence enhances benzodiazepine reinforcement.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although most patients taking BZDs as prescribed will not develop BZD use disorder, the risk of physical dependence and BZD use disorder increases with time, particularly in patients who use alcohol or other substances.31”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [31]
In the citing paper
“Thus, it is important to note that, even though zolpidem does not seem to engender any obvious tolerance development, zolpidem can lead to withdrawal symptoms that are comparable to those seen after chronic classical benzodiazepine treatment [29, 77].”
From Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective Receptor Modulators? (2012) · cites this paper as [77]
Citations
Cites
Risk Factors for Hip Fracture in White Women
Cummings, S. R., Nevitt, M. C., Browner, W. S., Stone, K., Fox, K. M., Ensrud, K. E., Cauley, J., Black, D., & Vogt, T. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503233321202 · Cited by 3,595
Psychotropic Drug Use and the Risk of Hip Fracture
Ray, W. A., Griffin, M. R., Schaffner, W., Baugh, D. K., & Melton, L. J. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702123160702 · Cited by 1,000
American drinking practices : a national study of drinking behavior and attitudes
Cahalan, D., Cisin, I. H., & Crossley, H. M. (1969) · Medical Entomology and Zoology · Cited by 637
Benzodiazepines: use, abuse, and consequences.
Woods, J. H., Katz, J. L., & Winger, G. (1992) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00468-5 · Cited by 560
Benzodiazepines of Long and Short Elimination Half-life and the Risk of Hip Fracture
Ray, W. A. (1989) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1989.03430230088031 · Cited by 548
Psychoactive Drugs and the Risk of Injurious Motor Vehicle Crashes in Elderly Drivers
Ray, W. A., Fought, R. L., & Decker, M. D. (1992) · American Journal of Epidemiology · doi:10.1093/aje/136.7.873 · Cited by 417
Benzodiazepines, memory and mood: a review
Valerie Curran, H. (1991) · Psychopharmacology · doi:10.1007/bf02316856 · Cited by 401
Withdrawal Reaction after Long-Term Therapeutic Use of Benzodiazepines
Busto, U., Sellers, E. M., Naranjo, C. A., Cappell, H., Sanchez-Craig, M., & Sykora, K. (1986) · New England Journal of Medicine · doi:10.1056/nejm198610023151403 · Cited by 369
Long-term Therapeutic Use of Benzodiazepines: I. Effects of Abrupt Discontinuation
Rickels, K. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220015002 · Cited by 332
Goa, K. L., & Ward, A. (1986) · Drugs · doi:10.2165/00003495-198632020-00002 · Cited by 332
Cited by
Polydrug abuse: a review of opioid and benzodiazepine combination use
Jones, J. D., Mogali, S., & Comer, S. D. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.07.004 · Cited by 703
Benzodiazepines revisited—will we ever learn?
Lader, M. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03563.x · Cited by 573
The epidemiology of benzodiazepine misuse: A systematic review*
Votaw, V. R., Geyer, R., Rieselbach, M. M., & McHugh, R. K. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.02.033 · Cited by 479
The diagnosis and management of benzodiazepine dependence
Ashton, H. (2005) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000165594.60434.84 · Cited by 455
“The use of benzodiazepines as recreational drugs is a growing problem [ 16 ].”
BackgroundMedical Use, Illicit Use, and Diversion of Abusable Prescription Drugs
McCabe, S. E., Teter, C. J., & Boyd, C. J. (2006) · Journal of American College Health · doi:10.3200/jach.54.5.269-278 · Cited by 358
Benzodiazepines for PTSD: A Systematic Review and Meta-Analysis
GUINA, J., ROSSETTER, S. R., DeRHODES, B. J., NAHHAS, R. W., & WELTON, R. S. (2015) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000091 · Cited by 341
GHB: a new and novel drug of abuse
Nicholson, K. L., & Balster, R. L. (2001) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(00)00191-5 · Cited by 320
Sources of prescription drugs for illicit use
McCabe, S. E., & Boyd, C. J. (2005) · Addictive Behaviors · doi:10.1016/j.addbeh.2005.01.012 · Cited by 251
Benzodiazepines I: Upping the Care on Downers: The Evidence of Risks, Benefits and Alternatives
Guina, J., & Merrill, B. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7020017 · Cited by 253
“High rates of comorbidity suggest that PTSD and SUDs are functionally related, a concept supported by several studies indicating a pathway (likely related to corticotropin-releasing hormone and norepinephrine) whereby PTSD precedes substance use [69].”
BackgroundInfluentialGriffiths, R. R., & Johnson, M. W. (2005) · PubMed · Cited by 239
Self-citationGriffiths, B. S., Kuan, H. L., Ritz, K., Glover, L. A., McCaig, A. E., & Fenwick, C. (2004) · Microbial Ecology · doi:10.1007/s00248-002-2043-7 · Cited by 209
Effectiveness of current treatment approaches for benzodiazepine discontinuation: a meta‐analysis
Parr, J. M., Kavanagh, D. J., Cahill, L., Mitchell, G., & Young, R. M. (2009) · Addiction · doi:10.1111/j.1360-0443.2008.02364.x · Cited by 212
Rowlett, J. K., Platt, D. M., Lelas, S., Atack, J. R., & Dawson, G. R. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405621102 · Cited by 212
Carter, L. P., & Griffiths, R. R. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.04.003 · Cited by 211
Self-citationAbuse and dependence liability of benzodiazepine-type drugs: GABAA receptor modulation and beyond
Licata, S. C., & Rowlett, J. K. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.01.001 · Cited by 197
The predictive validity of the rat self-administration model for abuse liability
O’Connor, E. C., Chapman, K., Butler, P., & Mead, A. N. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.10.012 · Cited by 203
Vinkers, C. H., & Olivier, B. (2012) · Advances in Pharmacological Sciences · doi:10.1155/2012/416864 · Cited by 195
Spiteller, G. (2006) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2006.03.013 · Cited by 187
Principles of initial experimental drug abuse liability assessment in humans
Griffiths, R. R., Bigelow, G. E., & Ator, N. A. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(03)00098-x · Cited by 190
Self-citationREPLACING RELATIVE REINFORCING EFFICACY WITH BEHAVIORAL ECONOMIC DEMAND CURVES
Johnson, M. W., & Bickel, W. K. (2006) · Journal of the Experimental Analysis of Behavior · doi:10.1901/jeab.2006.102-04 · Cited by 187
Abuse Liability Assessment of Tobacco Products Including Potential Reduced Exposure Products
Carter, L. P., Stitzer, M. L., Henningfield, J. E., O'Connor, R. J., Cummings, K. M., & Hatsukami, D. K. (2009) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-09-0948 · Cited by 186
Association between Benzodiazepine Use and Dementia: A Meta-Analysis
Zhong, G., Wang, Y., Zhang, Y., & Zhao, Y. (2015) · PLOS ONE · doi:10.1371/journal.pone.0127836 · Cited by 164
Guidelines and methodological reviews concerning drug abuse liability assessment
Balster, R. L., & Bigelow, G. E. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(03)00097-8 · Cited by 170
McCabe, S. E. (2005) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2004.12.006 · Cited by 165
Behavioral analyses of GHB: Receptor mechanisms
Carter, L. P., Koek, W., & France, C. P. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.10.003 · Cited by 154
Seizures in Alzheimer Disease: Clinical and Epidemiological Data
Pandis, D., & Scarmeas, N. (2012) · Epiliepsy currents/Epilepsy currents · doi:10.5698/1535-7511-12.5.184 · Cited by 154
Wu, C., Wang, S.-C., Chang, I., & Lin, K. (2009) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181a65210 · Cited by 166
McCabe, S. E., West, B. T., & Wechsler, H. (2007) · Addiction · doi:10.1111/j.1360-0443.2006.01733.x · Cited by 148
McCabe, S. E., Cranford, J. A., & Boyd, C. J. (2006) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2006.03.006 · Cited by 145
Ramelteon: A Novel Hypnotic Lacking Abuse Liability and Sedative Adverse Effects
Johnson, M. W., Suess, P. E., & Griffiths, R. R. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1149 · Cited by 135
Self-citationPanhelainen, A. E., Möykkynen, T. P., & Korpi, E. R. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.89 · Cited by 119
Adolescents' Access to Their Own Prescription Medications in the Home
Ross-Durow, P. L., McCabe, S. E., & Boyd, C. J. (2013) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2013.02.012 · Cited by 103
Acute behavioral effects and abuse potential of trazodone, zolpidem and triazolam in humans
Rush, C. R., Baker, R. W., & Wright, K. (1999) · Psychopharmacology · doi:10.1007/s002130050997 · Cited by 98
McCabe, S. E. (2008) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpediatrics.2007.41 · Cited by 102
Chronic benzodiazepine usage and withdrawal in insomnia patients
Poyares, D., Guilleminault, C., Ohayon, M. M., & Tufik, S. (2004) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2003.10.003 · Cited by 94
Hypnotics in Insomnia: The Experience of Zolpidem
MacFarlane, J., Morin, C. M., & Montplaisir, J. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.09.017 · Cited by 94
Reports of Memory Functioning by Patients With Chronic Pain
Muñoz, M., & Esteve, R. (2005) · Clinical Journal of Pain · doi:10.1097/01.ajp.0000173993.53733.2e · Cited by 105
Westra, H. A., Stewart, S. H., & Conrad, B. E. (2002) · Journal of Anxiety Disorders · doi:10.1016/s0887-6185(02)00091-9 · Cited by 97
Zaleplon and triazolam in humans: acute behavioral effects and abuse potential
Rush, C. R., Frey, J. M., & Griffiths, R. R. (1999) · Psychopharmacology · doi:10.1007/s002130051030 · Cited by 84
Self-citationGABAA receptor subtypes and benzodiazepine use, misuse, and abuse
Engin, E. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1060949 · Cited by 94
Defining Patterns of Benzodiazepine Use in Older Adults
Llorente, M. D., David, D., Golden, A. G., & Silverman, M. A. (2000) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/089198870001300309 · Cited by 77
Can valerian improve the sleep of insomniacs after benzodiazepine withdrawal?
Poyares, D. R., Guilleminault, C., Ohayon, M. M., & Tufik, S. B. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00305-0 · Cited by 77
Benzodiazepine prescription for patients in opioid maintenance treatment in Norway.
Bramness, J., & Kornør, H. (2007) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2007.03.008 · Cited by 68
Sleep and alertness disturbance and substance use disorders: A bi-directional relation
Roehrs, T., Sibai, M., & Roth, T. G. (2021) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2021.173153 · Cited by 78
Zolpidem-Related Effects on Performance and Mood During Simulated Night-Shift Work.
Hart, C. L., Ward, A. S., Haney, M., & Foltin, R. W. (2003) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.11.4.259 · Cited by 68
Carisoprodol use and abuse in Norway. A pharmacoepidemiological study
Bramness, J. G., Furu, K., Engeland, A., & Skurtveit, S. O. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.02847.x · Cited by 65
Ford, J. A., & Arrastia-Chisholm, M. C. (2008) · Addictive Behaviors · doi:10.1016/j.addbeh.2008.02.016 · Cited by 69
Anxiolytic-like effects of 8-acetylene imidazobenzodiazepines in a rhesus monkey conflict procedure
Fischer, B. D., Licata, S. C., Edwankar, R. V., Wang, Z.-J., Huang, S., He, X., Yu, J., Zhou, H., Johnson, E. M., Cook, J. M., et al. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.08.011 · Cited by 66
Hausken, A. M., Furu, K., Skurtveit, S. O., Engeland, A., & Bramness, J. G. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0565-8 · Cited by 59
The Role of a Prescription in Anxiety Medication Use, Abuse, and Dependence
Fenton, M. C., Keyes, K. M., Martins, S. S., & Hasin, D. S. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09081132 · Cited by 63
Effects of GABAergic modulators on food and cocaine self-administration in baboons
Weerts, E. M., Froestl, W., & Griffiths, R. R. (2005) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2005.05.006 · Cited by 53
Self-citationCentral Nervous System Depressants
Schuckit, M. A. (2000) · Springer eBooks · doi:10.1007/978-1-4757-3232-0_2 · Cited by 53
Off-Label Use of Antipsychotic Drugs
Weiss, E. M., Hummer, M., Koller, D., Ulmer, H., & Fleischhacker, W. W. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200012000-00018 · Cited by 53
Atack, J. R. (2009) · Advances in Pharmacology · doi:10.1016/s1054-3589(08)57004-9 · Cited by 52
Brunner, E., Chen, C.-Y. A., Klein, T., Maust, D., Mazer-Amirshahi, M., Mecca, M., Najera, D., Ogbonna, C., Rajneesh, K. F., Roll, E., et al. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09499-2 · Cited by 51
“31 Long-term BZD use is often associated with more risks than benefits.”
Svarstad, B. L., & Mount, J. K. (2001) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2001.t01-1-49278.x · Cited by 50
Reynolds, L. M., Engin, E., Tantillo, G., Lau, H. M., Muschamp, J. W., Carlezon, W. A., & Rudolph, U. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.115 · Cited by 49
Modest abuse-related subjective effects of zolpidem in drug-naive volunteers
Licata, S. C., Mashhoon, Y., MacLean, R. R., & Lukas, S. E. (2011) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e328343d78a · Cited by 50
Estimated magnitude of diversion and abuse of opioids relative to benzodiazepines in France
Pauly, V., Pradel, V., Pourcel, L., Nordmann, S., Frauger, É., Lapeyre‐Mestre, M., Micallef, J., & Thirion, X. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.03.009 · Cited by 51
A Multi-Agent Extension of a Hierarchical Task Network Planning Formalism
Cardoso, R. C., & Bordini, R. H. (2017) · ADCAIJ ADVANCES IN DISTRIBUTED COMPUTING AND ARTIFICIAL INTELLIGENCE JOURNAL · doi:10.14201/adcaij201762517 · Cited by 61
Medical and nonmedical use of prescription benzodiazepine anxiolytics among U.S. high school seniors
McCabe, S. E., & West, B. T. (2014) · Addictive Behaviors · doi:10.1016/j.addbeh.2014.01.009 · Cited by 46
Fitzgerald, A. C., Wright, B. T., & Heldt, S. A. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3457-x · Cited by 53
Local GABAA Receptor-Mediated Suppression of Dopamine Release within the Nucleus Accumbens
Brodnik, Z. D., Batra, A., Oleson, E. B., & España, R. A. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00268 · Cited by 46
Schoedel, K. A., Sun, H., Sellers, E. M., Faulknor, J., Levy‐Cooperman, N., Li, X., Kennedy, W. P., Cha, J., Lewis, N. M., Liu, W., et al. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000516 · Cited by 43
Sickle, B. J. V., Xiang, K., & Tietz, E. I. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300531 · Cited by 49
Wright, B. T., Gluszek, C. F., & Heldt, S. A. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3473-x · Cited by 42
Engin, E., Bakhurin, K. I., Smith, K. S., Hines, R. M., Reynolds, L. M., Tang, W., Sprengel, R., Moss, S. J., & Rudolph, U. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.41 · Cited by 40
Mini, L. J., Wang‐Weigand, S., & Zhang, J. (2007) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2007.09.004 · Cited by 41
Salzman, C. (1998) · Psychiatric Quarterly · doi:10.1023/a:1022125929946 · Cited by 40
Intravenous Drug Injection Habits: Drug Users’ Self-Reports versus Researchers’ Perception
Zernig, G., Giacomuzzi, S. M., Riemer, Y., Wakonigg, G., Šturm, K., & Saria, A. (2003) · Pharmacology · doi:10.1159/000068731 · Cited by 40
An abuse liability comparison of flunitrazepam and triazolam in sedative drug abusers
Mintzer, M. Z., & Griffiths, R. R. (2005) · Behavioural Pharmacology · doi:10.1097/01.fbp.0000172736.11994.3c · Cited by 39
Self-citationFlunitrazepam and triazolam: a comparison of behavioral effects and abuse liability
Mintzer, M. Z., & Griffiths, R. R. (1998) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(98)00110-0 · Cited by 41
Self-citationBeer, B., Clody, D. E., Mangano, R. M., Levner, M., Mayer, P. E., & Barrett, J. E. (1997) · CNS Drug Reviews · doi:10.1111/j.1527-3458.1997.tb00324.x · Cited by 39
Ator, N. A., & Griffiths, R. R. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36923-x · Cited by 39
Self-citationWeerts, E. M., Goodwin, A., Griffiths, R. R., Brown, P. R., Froestl, W., Jakobs, C., & Gibson, K. M. (2005) · Psychopharmacology · doi:10.1007/s00213-004-2079-0 · Cited by 38
Self-citationSchelp, S. A., Brodnik, Z. D., Rakowski, D. R., Pultorak, K. J., Sambells, A. T., España, R. A., & Oleson, E. B. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.241802 · Cited by 39
Comparison of the intravenous reinforcing effects of propofol and methohexital in baboons
Weerts, E. M., Ator, N. A., & Griffiths, R. R. (1999) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(99)00044-7 · Cited by 37
Self-citationRowlett, J. K., Lelas, S., Tornatzky, W., & Licata, S. C. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0228-8 · Cited by 41
Rada, P. V., & Hoebel, B. G. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.12.016 · Cited by 39
Rowlett, J. K., Winger, G. D., Carter, R. B., Wood, P. L., Woods, J. H., & Woolverton, W. L. (1999) · Psychopharmacology · doi:10.1007/s002130051050 · Cited by 36
Rowlett, J. K., Cook, J. M., Duke, A. N., & Platt, D. M. (2005) · CNS Spectrums · doi:10.1017/s1092852900009895 · Cited by 40
Modulation of rate of onset and intensity of drug effects reduces abuse potential in healthy males
Roset, P. N., Farré, M., de la Torre, R., Más, M., Menoyo, E., Hernández, C., & Camı́, J. (2001) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(01)00127-2 · Cited by 35
de la Peña, J. B., Lee, H. C., Peña, I. D., Woo, T. S., Yoon, S. Y., Lee, H. L., Han, J. S., Lee, J. I., Cho, Y. J., Shin, C. Y., et al. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.05.038 · Cited by 36
Les problèmes posés par l’utilisation des benzodiazépines chez le patient âgé
Bourin, M. (2010) · L Encéphale · doi:10.1016/j.encep.2010.04.016 · Cited by 35
Lile, J. A., Kelly, T. H., Pinsky, D. J., & Hays, L. R. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1393-3 · Cited by 35
Xiang, K., Earl, D. E., Davis, K. M., Giovannucci, D. R., Greenfield, L. J., & Tietz, E. I. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.144444 · Cited by 35
Nordfjærn, T., Bjerkeset, O. A., Bratberg, G. H., Moylan, S., Berk, M., & Gråwe, R. W. (2013) · Nordic Journal of Psychiatry · doi:10.3109/08039488.2013.775342 · Cited by 30
Dazzi, L., Serra, M., Spiga, F., Pisu, M. G., Jentsch, D., & Biggio, G. (2001) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(01)00105-5 · Cited by 37
Drug Misuse and Diversion in Adults Prescribed Anxiolytics and Sedatives
McLarnon, M. E., Monaghan, T. L., Stewart, S. H., & Barrett, S. P. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.3.262 · Cited by 30
Nordfjærn, T. (2012) · Addictive Behaviors · doi:10.1016/j.addbeh.2012.05.017 · Cited by 32
Effects of diazepam on conditioned place preference induced by morphine or amphetamine in the rat
Leri, F., & Franklin, K. B. J. (2000) · Psychopharmacology · doi:10.1007/s002130000448 · Cited by 28
Rowlett, J. K., & Lelas, S. (2007) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.15.4.328 · Cited by 27
Shinday, N. M., Sawyer, E. K., Fischer, B. D., Platt, D. M., Licata, S. C., Atack, J. R., Dawson, G. R., Reynolds, D. S., & Rowlett, J. K. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.265 · Cited by 27
Correlates of Dependence and Beliefs About the Use of Hypnotics Among Zolpidem and Zopiclone Users
Yen, C., Yen, C., Ko, C., Hwang, T., Chen, C., Chen, T., Su, P., Chen, S., & Lin, J. (2014) · Substance Use & Misuse · doi:10.3109/10826084.2014.980955 · Cited by 28
Lelas, S., Rowlett, J. K., Spealman, R. D., Cook, J. M., Ma, C., Li, X., & Yin, W. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1037-y · Cited by 25
Pharmacodynamic and receptor binding changes during chronic lorazepam administration
Fahey, J. M., Pritchard, G. A., Grassi, J. M., Pratt, J. S., Shader, R. I., & Greenblatt, D. J. (2001) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(01)00507-x · Cited by 27
Svarstad, B. L., & Mount, J. K. (2002) · Psychiatric Services · doi:10.1176/appi.ps.53.9.1159 · Cited by 28
The use of benzodiazepines in the aged patient: clinical and pharmacological considerations.
Dailly, É., & Bourin, M. (2008) · PubMed · Cited by 26
Reinforcing effects of diazepam under anxiogenic conditions in individuals with social anxiety.
Helmus, T. C., Tancer, M. E., & Johanson, C. (2005) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.13.4.348 · Cited by 24
Tjagvad, C., Clausen, T., Handal, M., & Skurtveit, S. O. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-0881-y · Cited by 24
Metadata
- Authors
- Griffiths, R. R., & Weerts, E. M.
- Affiliations
- Johns Hopkins University (US)
- Venue
- Psychopharmacology
- Published
- 1997-11-03
- Volume
- 134
- Issue
- 1
- Pages
- 1-37
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2038299708
- Cited by
- 260
- References
- 205
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 3 · 2023: 6 · 2022: 2 · 2021: 6 · 2020: 27 · 2019: 7 · 2018: 5 · 2017: 7 · 2016: 13 · 2015: 7 · 2014: 12 · 2013: 9 · 2012: 16
- FWCI
- 5.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- DigitalGeorgetown (Georgetown University Library) (submittedVersion)
- Funders
- National Institutes of Health (5r01da001147-28)
- National Institute on Drug Abuse (R01DA003889, R01 DA01147, R01DA03889)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- benzodiazepines, self-administration, drug reinforcement, recreational drug abuse, polydrug abuse, memory impairment, benzodiazepine withdrawal syndrome, physical dependence, chronic pain patients, alcoholics, sedatives, anxiolytics, insomnia
- MeSH terms
- Animals, Benzodiazepines, Humans, Self Administration, Anti-Anxiety Agents, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.